DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02928471

IM-LOSEIT-I

Completed

Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss

Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis Following a Significant Weight Loss, Investigating the Impact on Inflammation (A Substudy to "Effect of Liraglutide on Body Weight and Pain in Overweight or Obese Patients With Knee Osteoarthritis: A Randomised, Double Blind, Placebo-controlled, Parallel Group, Single-centre Trial" (NCT02905864)

Lead sponsor

Henrik Gudbergsen

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

200

estimated

Study population

Obesity / overweight, Osteoarthritis

Key I/E criterion

—

Primary endpoint

•The degree of inflammation in the knee-joint (DCE-MRI)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02928471
Org study ID137.03

Timeline

Milestones

Study first posted2016-10-10estimated
Last update posted2019-03-25actual
Study start2016-11 (month precision)
Primary completion2019-02actual (month precision)
Study completion2019-03actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightOsteoarthritis

Eligibility

Who can enroll

Minimum age18 Years
Maximum age74 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Participants eligible for parent trial (NCT02905864), i.e. overweight/obese individuals with knee osteoarthritis

Eligibility criteria

•Same as parent trial (NCT02905864)

Further Exclusion Criteria

•Same as parent trial (NCT02905864)
•Usual exclusion criteria for MRI (i.e. pacemakers etc.)

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other clinical outcomes

6 endpoints
Primary/protocol endpoint

Change in the degree of inflammation in the knee-joint (DCE-MRI)

Time frame:Week -8 to 0

change from baseline, improvement

Secondary/protocol endpoint

Change in the degree of inflammation in the knee-joint (CE-MRI)

Time frame:Week -8 to 0

change from baseline, improvement

Secondary/protocol endpoint

Change in the degree of inflammation in the knee-joint (MRI)

Time frame:Week -8 to 0

change from baseline, improvement

Secondary/protocol endpoint

Change in cartilage composition

Time frame:Week -8 to 0

change from baseline, improvement

Secondary/protocol endpoint

Change in bone marrow lesions (BML)

Time frame:Week -8 to 0

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Prediction of clinical symptoms (KOOS pain) by the level of crystal deposition on dual-energy CT at week 0

Time frame:Week 0

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.